Navigation Links
BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million
Date:11/9/2009

entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 40 Years on the Leading Edge: Case Western Reserve Universitys Biomedical Engineering Department Commemorates Achievement, Looks to Future
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com
4. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
5. Biomedical Research Organization Launches Groundbreaking National TV Campaign
6. HUYA Bioscience Establishes First-Look Agreement With Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH)
7. Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medicals Subsidiary, Sanvita Inc.
8. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
9. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
10. ETC Biomedical Announces Chamber Sale in India
11. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the ... treated in a Phase 1b clinical trial of ... a proprietary small molecule,inhibitor of thioredoxin, a protein ... growth, survival and drug resistance of,many cancers., ...
... to Healthcare Organizations through CSC,s ... ... CSC (NYSE: CSC ) today,announced that its enterprise ... FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes and incorporates ...
... (OTC BB BSTC.OB-News) today announced that it sold ... stock priced at $15,per share for aggregate proceeds ... certain private investors on June 9, 2008. The ... at a premium over the,market price., BioSpecifics ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3CSC Adds Content Management to Hosted Healthcare Offering 2
(Date:9/21/2014)... years, new strains of bacteria have emerged that resist ... including drug-resistant forms of tuberculosis and staphylococcus, infect more ... 23,000. Despite the urgent need for new treatments, scientists ... the past decade. , MIT engineers have now turned ... gene-editing system that can disable any target gene, they ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... imaging technique to track the effects of next-generation nanomedicines ... Strathclyde academic. Professor Dr. M. N. V. Ravi ... of Pharmacy and Biomedical Sciences, believe an advanced form ... boost developments in the field of nanomedicines, the encapsulation ...
... the collaboration between Janssen, J&J Innovation, VIB, KU Leuven ... in translating basic molecular insights to diagnostics and therapeutics ... are committing up to 5 million Euros for this ... research projects from VIB, KU Leuven and UZ Leuven. ...
... obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be ... The 95th Annual Meeting & Expo of The Endocrine Society. ... 15 Adolescent Health (10 a.m. PDT): New insights ... conditions including eating disorders and gender identity disorder. ...
Cached Biology News:Nanomedicines' impact on patients under the microscope 2Nanomedicines' impact on patients under the microscope 3Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases 2
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 2800mL PYREX Fernbach-style culture flasks have triple ... flask bottom to achieve maximal oxygen transfer ... large marking spot., A wide range of ... including:, Polypropylene colored caps for ease ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: